胰岛素样生长因子结合蛋白-3在肝脏组织中的表达及意义

目的研究胰岛素样生长因子结合蛋白-3(Insulin-like growth factor binding protein-3,IGF-BP-3)在慢性肝炎、肝硬化及肝癌中的意义.方法收集11例正常肝组织、12例慢性肝炎、16例肝硬化及21例肝癌组织标本及临床资料.采用标记链霉素卵白素生物素(SABC)法,用抗IGFBP-3单克隆抗体(Sigma,14527)行免疫组织化学染色.结果正常对照、慢性肝炎、肝硬化及肝癌肝组织中IGFBP-3的表达阳性率分别为100.00%(11/11),100.00%(12/12),87.50%(14/16)及42.86%(9/21).采用Ridit分析,其IGFBP-3表达强度的R±SR值分别为0.7462±0.0288,0.6589±0.0413,0.5344±0.0610,0.2330±0.0373,R±1.96SR分别为0.6898～0.8026,0.6149～0.7767,0.4148～0.6540,0.159～0.3061.肝癌组织中IGFBP-3的表达强度明显低于肝硬化、慢性肝炎及正常对照肝组织(P＜0.05);肝硬化肝组织明显低于正常肝组织(P＜0.05);而在肝硬化与慢性肝炎肝组织之间,以及慢性肝炎肝组织与正常肝组织之间无显著区别(P＞0.05).结论肝组织中IGFBP-3的表达强度可反映肝功能的损害程度.肝癌组织中IGFBP-3的表达强度显著降低.

Immunohistochemical localization and clinical significance of insulin-like growth factor binding protein-3 in liver tissues

Objective: To investigate the expression of insulin-like growth factor binding protein-3 (IGFBP-3)and its clinical significance in liver tissues with chronic hepatitis, liver cirrhosis, hepatocellular carcinoma (HCC)and healthy controls. Methods: 60 patients were recruited, including 12 cases of chronic hepatitis (mild, 2; moderate, 10), 16 cases of liver cirrhosis (Child A, 9; Child B, 4; Child C, 3; respectively), 21 cases of HCC and 11 cases of healthy controls. Immunohistochemical staining for IGFBP-3 was performed by SABC method. Results: The positive immunostaining rate of IGFBP-3 in liver tissues of healthy controls, chronic hepatitis, liver cirrhosis and HCC were 100.00% (11/11), 100.00% (12/12), 87.50% (14/16) and 42.86% (9/21), respectively. By Ridit test, the R ±SR value of the immunostaining intensity of IGFBP-3 were 0.7462 ± 0.0288, 0.6958 ± 0.0413, 0.5344 ± 0.0610,0.2330 ± 0.0373, respectively; and the value of R ± 1.96SR were 0.6898～0.8026, 0.6149～0.7767, 0.4148～0.6540,0.1599～0.3061, accordingly. The intensity of staining in HCC tissues was significantly lower than in the other three groups ( P ＜0.05). A decreased expression of IGFBP-3 in liver cirrhosis was found compared to normal controls ( P ＜0.05). But there wasn't statistically significant difference between liver cirrhosis and chronic hepatitis (P＞0.05) and between chronic hepatitis and normal controls ( P ＞0.05). Conclusion: The expression intensity of IGFBP-3 in liver tissues with cirrhosis and chronic hepatitis decreases and reflects the damage degree of liver function. The inhibition of apoptosis and enhanced proliferation of hepatocytes due to significantly reduced expression of IGFBP-3 in HCC may be involved in hepatocarcinogenesis.